Investigators Report Series of Substates that Reprogram IgG to 1-Step Synthesis of gsADCs
June 20th 2022Glycosite-specific antibody‒drug conjugates (gsADCs), harnessing Asn297 N-glycan of IgG Fc as the conjugation site for drug payloads, usually require multi-step glycoengineering with 2 or more enzymes, which limits the substrate diversification and complicates the preparation process.
Read More
Oncology Overview: Selpercatinib in the Treatment of Medullary Thyroid Cancer
June 17th 2022Selpercatinib (Retevmo, Loxo Oncology) is FDA-approved to treat 3 types of tumors—metastatic RET fusion-positive non-small cell lung cancer, advanced medullary thyroid cancer (MTC) or MTC that has spread, and advanced RET fusion-positive thyroid cancer.
Read More